NEW BRUNSWICK (dpa-AFX) - Johnson & Johnson (JNJ) reported positive topline
results from the Phase 3 GRAVITI investigational study of TREMFYA subcutaneous
induction therapy in adult patients with moderately to severely active Crohn's
disease. The study met both co-primary endpoints, achieving statistically
significant and clinically meaningful outcomes for clinical remission at Week 12
as well as endoscopic response at Week 12. Safety data from GRAVITI were
consistent with the safety profile of TREMFYA in its approved indications.

'The Phase 3 GRAVITI study showed promising results with subcutaneous induction
and provides similar clinical benefit to what was seen with IV induction in the
GALAXI studies,' said David Lee, Global Therapeutic Area Head Immunology,
Johnson & Johnson Innovative Medicine.

For More Such Health News, visit rttnews.com.



Copyright(c) 2024 RTTNews.com. All Rights Reserved

Copyright RTT News/dpa-AFX